Skip to content
Screener

Total Revenue at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$11.99B
Danaher logo
DanaherDHR
$6.27B+5.5%
Azenta logo
AzentaAZTA
$161.18M+12.0%
Agilent Technologies logo
Agilent TechnologiesA
$1.84B+10.0%
Illumina logo
IlluminaILMN
$1.16B+9.4%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$4.05M-76.3%

Segments

By geography

See full
Americas$64.31M+16.5%
EMEA$37.35M+21.9%
APAC$9.06M+30.1%

By product

See full
NGS applications$57.44M+12.3%
DNA synthesis and protein solutions$53.27M+27.9%

By segment

See full
Reportable Segment$110.72M+19.3%

Other financials

Income statement

See full
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$7.21B+361%
Enterprise value$7.2B+396%
P/S17.6×+13.3×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0001581280-26-000040
(In thousands, except per share data)Three months ended March 31, 2026Three months ended March 31, 2025Six months ended March 31, 2026Six months ended March 31, 2025
Revenues[1]$110,715$92,793$214,413$181,506
Costs and expenses:
Cost of revenues$53,593$46,765$103,319$92,638
Research and development expenses19,69523,91736,82545,224
Selling, general and administrative expenses[1]76,08563,671145,827119,849
Litigation settlement costs, net of recoveries7,2057,205
Total costs and expenses$156,578$134,353$293,176$257,711
Loss from operations$(45,863)$(41,560)$(78,763)$(76,205)

Item 1. Financial Statements (unaudited)

FAQ

What is Twist Bioscience Corporation's total revenue?
Twist Bioscience Corporation (TWST) reported total revenue of $110.72M in Q1 2026.
How has Twist Bioscience Corporation's total revenue changed year-over-year?
Twist Bioscience Corporation's total revenue increased by 19.3% year-over-year, from $92.79M to $110.72M.
What is the long-term trend for Twist Bioscience Corporation's total revenue?
Over 4 years (2021 to 2025), Twist Bioscience Corporation's total revenue has grown at a 29.9% compound annual growth rate (CAGR), from $132.33M to $376.57M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Twist Bioscience Corporation's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude